Business Context and Reporting Period
This Form 8-K Current Report was filed by Zentalis Pharmaceuticals, Inc. on April 8, 2022. The filing serves as a Regulation FD disclosure and report of other events, primarily announcing the release of initial efficacy and safety data from ongoing clinical trials for the Company's product candidates, ZN-c3 and ZN-c5, presented at the American Association of Cancer Research (AACR) Annual Meeting.
Key Financial Metrics
This filing is a current report regarding clinical developments and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The document notes in the forward-looking statements section that the Company has a need for additional funding, which may not be available.
Material Changes and Clinical Data
The primary material change reported is the disclosure of interim clinical data for the Company's pipeline:
- ZN-c3 in Ovarian Cancer (Phase 1b): In a trial combining ZN-c3 with chemotherapy for platinum-resistant or -refractory ovarian cancer, 56 patients were evaluated for safety and 43 were response-evaluable as of January 28, 2022. The overall Disease Control Rate (DCR) was 86.0% and the Overall Response Rate (ORR) was 30.2%. Notable cohort results included a 62.5% ORR in the ZN-c3 + paclitaxel cohort and a 45.5% ORR in the ZN-c3 + carboplatin cohort.
- ZN-c3 in Uterine Serous Carcinoma (Phase 1): Interim data from the monotherapy dose expansion cohort (n=12 evaluable) showed a DCR of 88.9% as of October 28, 2021, including one unconfirmed complete response.
- ZN-c5 in Breast Cancer (Phase 1/2): Initial data showed a Clinical Benefit Rate (CBR) of 34% in ER+/HER2- breast cancer patients (n=50) receiving ZN-c5 with palbociclib, and a 20% CBR in a cohort (n=10) receiving ZN-c5 with abemaciclib. Drug-drug interactions were observed at specific doses, though the Company does not expect interactions at relevant doses.
Outlook, Risks, and Management Commentary
Management highlighted the broad potential of ZN-c3 in multiple settings, including AML and PARP-resistant ovarian cancer, and noted ZN-c5's bone protectant activity which may position it for an adjuvant setting. The Company plans to initiate a combination study of ZN-c5 + ZN-c3 in ER+/HER2- CDK4/6i-resistant breast cancer patients in 2022.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers citing risks such as the impact of the COVID-19 pandemic, limited operating history, substantial dependence on lead product candidates, the early stage of development, potential clinical trial delays, regulatory approval uncertainties, and the need for additional funding.
Investor Verification Checklist
- Verify the specific dosing regimens and safety profiles for ZN-c3 in combination with different chemotherapies (PLD, carboplatin, paclitaxel) to assess tolerability.
- Confirm the timeline for the initiation of the planned ZN-c5 + ZN-c3 combination study in 2022.
- Review the Company's most recent Form 10-K or 10-Q for current cash runway and capital requirements, as this 8-K does not provide financial liquidity data.
- Monitor the resolution of drug-drug interaction (DDI) findings for ZN-c5 with CDK4/6 inhibitors to ensure dose optimization for future trials.
- Assess the durability of the unconfirmed complete response observed in the uterine serous carcinoma cohort.